Never Run Out Of Buyers To Sell To.

Curasight is founded in 2013 in Denmark based on a strong understanding of nuclear medicines and more than a decade of research at Copenhagen’s University hospital, Rigshospitalet and the University of Copenhagen, where the potential of targeting the urokinase-type plasminogen activator receptor (uPAR) in solid cancer tumors was identified. Led by Professor Andreas Kjær (CSO & Co-founder), the research demonstrated how uPAR could be used not only to visualize aggressive cancer biology through PET imaging, but also as a highly selective target for radionuclide therapy. These insights formed…
Built from contact records that share this company: name, job title, job level, job function and person location.
Turn cold outreach into meaningful business conversations.
Rated and recommended by professionals who expect more
Annual Revenue$10M to $25M
Estimated OwnershipPublicMatching runs on fields we already have: industry, employee range, HQ location, ownership type, funding rounds, specialities. Results come live from the ReachStream directory.